- Zacks•5 hours ago
What's in store for drug stocks Bristol-Myers, Amgen, Celgene, Alexion and Seattle Genetics when they report Q3 results on Oct 27?
- Business Wire•6 days agoSeattle Genetics Demonstrates Commitment to Improve Hodgkin Lymphoma Treatment Paradigm through Multiple ADCETRIS® (Brentuximab Vedotin) Data Presentations at ISHL 2016
Seattle Genetics, Inc. today highlighted multiple data presentations at the 10th International Symposium on Hodgkin Lymphoma taking place in Cologne, Germany, October 22-25, 2016, evaluating ADCETRIS across a broad range of Hodgkin lymphoma disease settings.
- American City Business Journals•9 days ago
Seattle Genetics has promoted Dr. Vaughn Himes to the new role of chief technical officer and Dr. Dennis Benjamin to senior vice president, translational research. The Bothell-based biotech firm also announced the appointment of Dr. Robert Lechleider as senior vice president, clinical development. Himes has been with Seattle Genetics (SGEN) since 2009.
Seattle Genetics, Inc. (SGEN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||50.35 x 100|
|Ask||50.40 x 300|
|Day's Range||49.79 - 50.70|
|52wk Range||26.02 - 57.83|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-65.65|
|Avg Vol (3m)||822,686|
|Dividend & Yield||N/A (N/A)|